← ANALYST RATINGS · TIPRANKS
Aquestive Therapeutics (AQST): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $8.67, the highest $10.00, the lowest $6.00. The average is +129.3% from the last price of $3.78.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $5.00 → $4.50−10.0% | Hold | +19.0% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $10.00 | Buy | +164.6% | Reiterated | 15.10.26on TipRanks 10:16 | −12.2%next day −5.8% | ↗ |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $5.00 → $4.50−10.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $5.00 → $4.50−10.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $5.00 | Hold | +32.3% | Reiterated | 29.09.26on TipRanks 16:05 | — | |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $10.00 | Buy | +164.6% | Reiterated | 17.09.26on TipRanks 10:26 | −4.5%next day −1.2% · 5 days +2.6% | ↗ |
| Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% | Lake Street | $6.00 | Buy | +58.7% | Reiterated | 17.09.26on TipRanks 09:10 | −4.5%next day −1.2% · 5 days +2.6% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $11.00 | Buy | +191.0% | Reiterated | 25.06.26on TipRanks Jun 26 08:15 | −10.7%next day −1.0% · 5 days −7.8% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $8.00 | Buy | +111.6% | Reiterated | 25.06.26on TipRanks 07:55 | −10.7%next day −1.0% · 5 days −7.8% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $9.00 | Buy | +138.1% | Reiterated | 15.05.26on TipRanks 11:20 | −10.6%next day −0.8% · 5 days −2.1% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $8.00 | Buy | +111.6% | Reiterated | 15.05.26on TipRanks 07:00 | −10.6%next day −0.8% · 5 days −2.1% | ↗ |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $9.00 | Buy | +138.1% | Reiterated | 14.05.26on TipRanks 17:05 | −10.6%next day −0.8% · 5 days −2.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Aquestive Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.67 at a price of $4.63 (+87.2%); now: $8.67 at $3.78 (+129.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 9 | 8 | 6 | 5 | 6 |
| Buy | 3 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.12 (from $-0.15 to $-0.09). Last quarter: $-0.18.
Sales
Next quarter’s sales estimate — $11M (from $10M to $12M). Last quarter: $14M.
Best top-analyst consensus in the sector · Healthcare
About Aquestive Therapeutics
- CEO: Daniel Barber
- Employees: 147
- 30 Technology Drive, Warren, NJ, 07059, US
- www.aquestive.com
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Data from the stock’s TipRanks forecast page, read 184 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗